In vitroandin vivopharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects

(2009) N. Parrott et al.   AAPS Journal

Aurora kinase inhibitors

(2009) J.J.E.M. Kitzen et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Relationship between Passive Permeability, Efflux, and Predictability of Clearance from In Vitro Metabolic Intrinsic Clearance

(2009) L. Huang et al.   DRUG METABOLISM AND DISPOSITION

Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents

(2009) John R. Pollard et al.   JOURNAL OF MEDICINAL CHEMISTRY

Current Methods for Predicting Human Food Effect

(2008) Kimberley A. Lentz   AAPS Journal

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY